लोड हो रहा है...

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines

There is an unmet medical need for later-line treatment options for patients with metastatic colorectal cancer (mCRC). Considering that, beyond progression, co-treatment with bevacizumab and cytotoxic chemotherapy showed less toxicity and a significant disease control rate, we aimed to evaluate the...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Sci Rep
मुख्य लेखकों: Bang, Yeong Hak, Kim, Jeong Eun, Lee, Ji Sung, Kim, Sun Young, Kim, Kyu-Pyo, Kim, Tae Won, Hong, Yong Sang
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Nature Publishing Group UK 2021
विषय:
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC8007566/
https://ncbi.nlm.nih.gov/pubmed/33782470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-86482-x
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!